What is Agenus?
Headquartered in Lexington, Massachusetts, Agenus is a clinical-stage biopharmaceutical company dedicated to the research, development, and manufacturing of innovative immuno-oncology products. The company distinguishes itself through its proprietary Retrocyte Display discovery engine, a sophisticated platform designed to generate fully human therapeutic antibody drug candidates. By integrating advanced science with a focus on patient-centric outcomes, Agenus addresses critical unmet needs in oncology, utilizing a diverse array of modalities including vaccines, adjuvants, and cell-based therapies to modulate the immune system effectively.
How much funding has Agenus raised?
Agenus has raised a total of $547.1M across 9 funding rounds:
Share Placement
$10M
Debt
$5M
Debt
$21.1M
Debt
$100M
Share Placement
$60M
Debt
$230M
Debt
$1M
Private Equity
$35M
Stock/Share Issuance
$85M
Share Placement (2009): $10M with participation from Downsview Capital, Iroquois Capital, and Hudson Capital Group
Debt (2013): $5M, investors not publicly disclosed
Debt (2015): $21.1M, investors not publicly disclosed
Debt (2015): $100M, investors not publicly disclosed
Share Placement (2017): $60M backed by Incyte
Debt (2018): $230M with participation from HealthCare Royalty Partners
Debt (2020): $1M led by PPP
Private Equity (2020): $35M supported by Betta Pharmaceuticals Co., Ltd.
Stock/Share Issuance (2026): $85M featuring Commodore Capital, TCG Crossover, Invus, Ligand Pharmaceuticals, and RA Capital Management
Key Investors in Agenus
Commodore Capital
Commodore Capital focuses on investing in innovative biopharmaceutical companies that aim to improve patients' lives through advancements in genetic medicines and cellular therapies.
TCG Crossover
TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines and supporting innovators in the pharmaceutical and biotechnology sectors.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in healthcare and life science companies, utilizing its TechAtlas think tank to support strategic decisions.
What's next for Agenus?
With the successful closure of this major strategic investment, Agenus is poised to enter a pivotal phase of operational scaling and clinical advancement. The company's strategic roadmap likely involves the acceleration of its lead candidates through late-stage clinical trials, alongside the continued optimization of its discovery engine to maintain a competitive edge in the rapidly evolving biopharmaceutical landscape. Investors and stakeholders are closely monitoring the firm's ability to translate its scientific breakthroughs into commercialized medical solutions. As Agenus transitions from a research-heavy entity to a more mature clinical-stage organization, the focus will remain on achieving regulatory milestones and establishing strategic partnerships that enhance the reach and efficacy of its therapeutic pipeline.
See full Agenus company page
